PER® Miami Breast Cancer Conference | Conference

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

March 10th 2025

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

March 9th 2025

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer

March 9th 2025

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases

March 8th 2025

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

March 8th 2025

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer

March 8th 2025

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups

March 8th 2025

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer

March 8th 2025

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

March 8th 2025

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas

March 8th 2025

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options

March 7th 2025

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer

March 7th 2025

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC

March 7th 2025

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer

March 7th 2025

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer

March 7th 2025

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer

March 7th 2025

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer

March 7th 2025

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population

March 7th 2025

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2-Negative Metastatic Breast Cancer

March 7th 2025

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.